Veradigm | MDRX - Cost Of Sales


Veradigm reported $124.74M in Cost of Sales for its fiscal quarter ending in December of 2022.





Cost Of Sales Change Date
Alcidion AUD 6.82M 1.16M Dec/2025
Ambu A/S DKK 625M 14M Mar/2026
Amplifon EUR -241.7M 701.87M Dec/2025
Cardinal Health USD 58.54B 4.82B Mar/2026
Centene USD 44.39B 3.2B Mar/2026
Charles River Laboratories USD 716.51M 5.76M Mar/2026
Cigna USD 62.41B 4.1B Mar/2026
Coloplast 2.31B 110M Dec/2025
Computer Programs Systems USD 52.17M 9.8M Dec/2025
Convatec Group USD 515.3M 270.15M Dec/2024
CVS Health USD 84.8B 7.32B Mar/2026
Diasorin EUR 101M 7.58M Mar/2026
Elevance Health USD 38.07B 75M Dec/2025
General Electric Aerospace USD 8.15B 764M Mar/2026
Gulf Medical Proj AED 151.05M 11.52M Dec/2025
Humana USD 26.54B 1.15B Mar/2025
IQVIA Holdings USD 3.08B 161M Mar/2026
Laboratory Of America USD 2.6B 4.2M Mar/2026
Maximus USD 984M 62.68M Mar/2026
McKesson USD 92.25B 10.22B Mar/2026
Med Life RON 283.78M 123.71M Sep/2025
Molina Healthcare USD 9.77B 406M Mar/2026
Omnicell USD 169.52M 14.14M Mar/2026
Oriola-kd EUR 461.6M 35.5M Dec/2025
Owens Minor USD 436.92M 32.62M Dec/2025
Quest Diagnostics USD 1.99B 57M Mar/2026
Rede D'or Sao Luiz BRL 11.12B 4.84B Mar/2026
Siemens Healthineers EUR 3.54B 214M Mar/2026
Sonova Holding CHF 539.4M 11.5M Dec/2025
UnitedHealth USD 94.72B 2.2B Dec/2025
Veeva Systems USD 220.92M 7.45M Mar/2026
Veradigm USD 124.74M 56.25M Dec/2022
Xerox USD 1.14B 104M Jun/2025